Umbilical cord–derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data

Colicchia, Martina; Jones, Daniel A.; Beirne, Anne‐Marie; Hussain, Mumtaz; Weeraman, Deshan; Rathod, Krishnaraj S.; Veerapen, Jessry; Lowdell, Mark W.; Mathur, Anthony

doi:10.1016/j.jcyt.2019.04.056

Cited by 23 publications

(22 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human umbilical cord MSCs (hUC-MSCs) emerged recently as an attractive source of MSCs for clinical application. The hUC-MSCs not only share the same features such as multiline age differentiation, paracrine functions, and immunomodulatory properties as well as of all MSCs, but also have some unique advantages, such as non-required for bone marrow matching, low immunogenicity, higher self-renewal capacities, and for accelerating injury tissue repair processes [9][10]. Our previous experiments had demonstrated that severe burns could bring a systemic inflammatory reaction.…”

Section: Introductionmentioning

confidence: 99%

Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Acute Lung Injury Caused by Severe Burn via Secreting TSG-6 and Inhibiting Inflammatory Response

Liu

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives To investigate whether hUC-MSCs attenuated severe burn-induced ALI and the effects were based on TSG-6 secreted from hUC-MSCs. Method Rat model was established and evaluated as follows：cytokine expression was measured by ELISA assay, and both inflammatory cell infiltration and lung injury were assessed by immunohistochemistry assay. Results In vitro, TSG-6 levels in serum from the burn group were significantly increased than that of the sham group. In vivo, TSG-6 levels of lung tissues and serum in the burn+ hUC-MSCs group were significantly increased than those of that in the burn group. Both in lung tissues and serum, increased levels of proinflammatory cytokines（TNF-α, IL-1β, IL-6）were remarkably decreased, but anti-inflammatory cytokine IL-10 increased after hUC-MSCs administration (p<0.05). These significant positive effects after hUC-MSCs transplantation did not occur in the Burn+siTSG-6 group. Conclusion Intra-tracheal implantation of hUC-MSCs has been an effective treatment for severe burn-induced ALI via promoting TSG-6 secretion and inhibiting inflammatory reaction in lung tissue.

show abstract

Section: Introductionmentioning

confidence: 99%

Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Acute Lung Injury Caused by Severe Burn via Secreting TSG-6 and Inhibiting Inflammatory Response

Liu

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…MSCs secrete growth factors and chemokines which induce cardio-protection, stimulate angiogenesis, and reorganize the extracellular matrix in ischemic scar areas. Several clinical studies have described how the use of MSCs improved cardiac function and the regeneration of heart tissue in damaged hearts [ 1 – 3 ].…”

Section: Introductionmentioning

confidence: 99%

Application of mesenchymal stem cell sheet to treatment of ischemic heart disease

et al. 2021

View full text Add to dashboard Cite

In recent years, mesenchymal stem cells (MSCs) have been used to improve cardiac function and attenuate adverse ventricular remodeling of the ischemic myocardium through paracrine effects and immunoregulation functions. In combination with cell sheet technology, MSCs could be more easily transplanted to the ischemic area. The long-term retention of MSCs in the affected area was realized and significantly improved the curative effect. In this review, we summarized the research and the applications of MSC sheets to the treatment of ischemic heart tissue. At present, many types of MSCs have been considered as multipotent cells in the treatment of heart failure, such as bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), umbilical cord-derived mesenchymal stem cells (UC-MSCs), and skeletal myoblasts (SMs). Since UC-MSCs have few human leukocyte antigen-II and major histocompatibility complex class I molecules, and are easy to isolate and culture, UC-MSC sheets have been proposed as a candidate for clinical applications to ischemic heart disease.

show abstract

“…Clear-cut evidence on what type of cells should be adopted to CIC is still lacking, because results show significant heterogeneity in terms of efficacy. Most clinical trials used autologous bone marrow mononuclear cells (BM-MNCs), which comprise predominantly mononuclear cells, with small sub-populations of hematopoietic stem cells and mesenchymal stromal cells (MSC) (3,4). According to two meta-analysis of more than 20 clinical trials on the effectiveness of BM-MNCs for cardiac regeneration following acute myocardial infarction (MI), it is clear that no significant improvement was observed in the mortality and morbidity of patients who received BM-MNCs, although a significant and sustained improvement in left ventricular ejection fraction (LVEF) was reported (5,6).…”

Section: Introductionmentioning

confidence: 99%

Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial)

Ulus

Mungan

Kurtoğlu

et al. 2020

IJSC

View full text Add to dashboard Cite

Background and Objectives: The HUC-HEART Trial (ClinicalTrials.gov Identifier: NCT02323477) was a controlled, prospective, phase I/II, multicenter, single-blind, three-arm randomized study of intramyocardial delivery of human umbilical cord-derived mesenchymal stromal cells (HUC-MSCs) combined with coronary artery bypass-grafting (CABG) in patients with chronic ischemic cardiomyopathy (CIC). The trial aimed to assess (i) the safety and the efficacy of cell transplantation during one-year follow-up, (ii) to compare the efficacy of HUC-MSCs with autologous bone-marrow-derived mononuclear cells (BM-MNCs) in the same clinical settings. Methods and Results: Fifty-four patients who were randomized to receive HUC-MSCs (23×10 6) (n=26) or BM-MNCs (70×10 7) (n=12) in combination with CABG surgery. The control patients (n=16) received no cells/vehicles but CABG intervention. All patients were screened at baseline and 1, 3, 6, 12 months after transplantation. Forty-six (85%) patients completed 12 months follow-up. No short/mid-term adverse events were encountered. Decline in NT-proBNP (baseline∼ 6 months) in both cell-treated groups; an increase in left ventricular ejection fraction (LVEF) (5.4%) and stroke volume (19.7%) were noted (baseline∼6 or 12 months) only in the HUC-MSC group. Decreases were also detected in necrotic myocardium as 2.3% in the control, 4.5% in BM-MNC, and 7.7% in the HUC-MSC groups. The 6-min walking test revealed an increase in the control (14.4%) and HUC-MSC (23.1%) groups. Conclusions: Significant findings directly related to the intramyocardial delivery of HUC-MSCs justified their efficacy in CIC. Stricter patient selection criteria with precisely aligned cell dose and delivery intervals, rigorous follow-up by detailed diagnostic approaches would further help to clarify the responsiveness to the therapy.

show abstract

Umbilical cord–derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data

Cited by 23 publications

References 94 publications

Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Acute Lung Injury Caused by Severe Burn via Secreting TSG-6 and Inhibiting Inflammatory Response

Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Acute Lung Injury Caused by Severe Burn via Secreting TSG-6 and Inhibiting Inflammatory Response

Application of mesenchymal stem cell sheet to treatment of ischemic heart disease

Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial)

Contact Info

Product

Resources

About